US Patent Issued to UCB Biopharma on June 9 for "Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-ylethanone" (Belgian Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,649,754, issued on June 9, was assigned to UCB Biopharma SRL (Brussels).

"Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-ylethanone" was invented by Ali Ates (Brussels), Celal Ates (Brussels) and Laurent Provins (Brussels).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a prodrug of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone, which prodrug is represented by formula (II)."

The patent was filed on Dec. 16, 2021, under Applic...